Cartesian Therapeutics, Inc. Stock-Based Compensation
Cartesian Therapeutics, Inc. (RNAC) reported Stock-Based Compensation of $4.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Cartesian Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.08M, a 36.47% decline year-over-year.
- Cartesian Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.42M, a 3.39% decline year-over-year.
- Cartesian Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.14M, a 14.96% increase year-over-year.
- Cartesian Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.59M, a 52.80% increase year-over-year.
- Cartesian Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $10.52M, a 59.85% increase from fiscal 2024.
- Cartesian Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $6.58M, a 70.78% decline from fiscal 2023.
- Cartesian Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $22.52M, a 101.21% increase from fiscal 2022.
- Cartesian Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $11.19M, a 45.00% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.51M 10-Q · filed 2026-08-06 | $6.65M derived: sum of 3 quarters · filed 2026-08-06 | $9.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.42M 10-Q · filed 2026-04-30 | $4.57M derived: sum of 2 quarters · filed 2026-04-30 | $7.16M derived: sum of 3 quarters · filed 2026-04-30 | $10.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $4.73M derived: sum of 2 quarters · filed 2026-03-09 | $8.01M derived: sum of 3 quarters · filed 2026-08-06 | $10.52M 10-K · filed 2026-03-09 |
| 2025-09-30 | $2.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.87M derived: sum of 2 quarters · filed 2026-08-06 | $8.38M 10-Q · filed 2025-11-06 | $10.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.79M 10-Q · filed 2026-08-06 | $7.65M derived: sum of 3 quarters · filed 2026-08-06 | $9.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.51M 10-Q · filed 2026-04-30 | $4.37M derived: sum of 2 quarters · filed 2026-04-30 | $6.07M derived: sum of 3 quarters · filed 2026-04-30 | $7.66M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $3.56M derived: sum of 2 quarters · filed 2026-03-09 | $5.15M derived: sum of 3 quarters · filed 2026-03-09 | $6.58M 10-K · filed 2026-03-09 |
| 2024-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.29M derived: sum of 2 quarters · filed 2025-11-06 | $4.72M 10-Q · filed 2025-11-06 | $18.86M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.02M 10-Q · filed 2025-08-07 | $17.17M derived: sum of 3 quarters · filed 2025-08-07 | $19.49M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.43M 10-Q · filed 2025-05-08 | $15.57M derived: sum of 2 quarters · filed 2025-05-08 | $17.90M derived: sum of 3 quarters · filed 2025-05-08 | $21.68M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $14.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $16.46M derived: sum of 2 quarters · filed 2025-03-13 | $20.25M derived: sum of 3 quarters · filed 2025-03-13 | $22.52M 10-K · filed 2025-03-13 |
| 2023-09-30 | $2.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.10M derived: sum of 2 quarters · filed 2024-11-07 | $8.38M 10-Q · filed 2024-11-07 | $10.66M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $6.06M 10-Q · filed 2024-08-08 | $8.34M derived: sum of 3 quarters · filed 2024-08-08 | $10.94M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.28M 10-Q · filed 2024-05-08 | $4.55M derived: sum of 2 quarters · filed 2024-05-08 | $7.15M derived: sum of 3 quarters · filed 2024-05-08 | $10.72M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $4.88M derived: sum of 2 quarters · filed 2024-03-07 | $8.44M derived: sum of 3 quarters · filed 2024-03-07 | $11.19M 10-K · filed 2024-03-07 |
| 2022-09-30 | $2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $6.17M derived: sum of 2 quarters · filed 2023-11-13 | $8.92M 10-Q · filed 2023-11-13 | $11.17M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $3.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-17 | $6.32M 10-Q · filed 2023-08-17 | $8.57M derived: sum of 3 quarters · filed 2024-03-07 | $10.47M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $2.75M 10-Q · filed 2023-05-04 | $5.01M derived: sum of 2 quarters · filed 2024-03-07 | $6.91M derived: sum of 3 quarters · filed 2024-03-07 | $8.69M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $4.16M derived: sum of 2 quarters · filed 2024-03-07 | $5.94M derived: sum of 3 quarters · filed 2024-03-07 | $7.72M 10-K · filed 2024-03-07 |
| 2021-09-30 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $3.69M derived: sum of 2 quarters · filed 2022-11-03 | $5.47M 10-Q · filed 2022-11-03 | $6.70M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $1.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $3.56M 10-Q · filed 2022-08-08 | $4.80M derived: sum of 3 quarters · filed 2023-03-02 | $6.09M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $1.78M 10-Q · filed 2022-05-05 | $3.02M derived: sum of 2 quarters · filed 2023-03-02 | $4.31M derived: sum of 3 quarters · filed 2023-03-02 | $5.79M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $2.53M derived: sum of 2 quarters · filed 2023-03-02 | $4.01M derived: sum of 3 quarters · filed 2023-03-02 | $5.42M 10-K · filed 2023-03-02 |
| 2020-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $2.78M derived: sum of 2 quarters · filed 2021-11-09 | $4.19M 10-Q · filed 2021-11-09 | $5.61M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $2.89M 10-Q · filed 2021-08-12 | $4.32M derived: sum of 3 quarters · filed 2022-03-10 | $5.62M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $1.41M 10-Q · filed 2021-05-13 | $2.84M derived: sum of 2 quarters · filed 2022-03-10 | $4.14M derived: sum of 3 quarters · filed 2022-03-10 | $5.39M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $2.73M derived: sum of 2 quarters · filed 2022-03-10 | $3.98M derived: sum of 3 quarters · filed 2022-03-10 | $5.16M 10-K · filed 2022-03-10 |
| 2019-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $2.55M derived: sum of 2 quarters · filed 2020-11-05 | $3.73M 10-Q · filed 2020-11-05 | $5.52M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.43M 10-Q · filed 2020-08-06 | $4.22M derived: sum of 3 quarters · filed 2021-03-12 | $5.71M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $1.18M 10-Q · filed 2020-05-07 | $2.97M derived: sum of 2 quarters · filed 2021-03-12 | $4.46M derived: sum of 3 quarters · filed 2021-03-12 | |
| 2018-12-31 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $3.27M derived: sum of 2 quarters · filed 2021-03-12 | $5.71M 10-K · filed 2021-03-12 | |
| 2018-09-30 | $1.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $3.92M 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $2.44M 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | $4.08M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |